JP2024512386A5 - - Google Patents

Info

Publication number
JP2024512386A5
JP2024512386A5 JP2023555192A JP2023555192A JP2024512386A5 JP 2024512386 A5 JP2024512386 A5 JP 2024512386A5 JP 2023555192 A JP2023555192 A JP 2023555192A JP 2023555192 A JP2023555192 A JP 2023555192A JP 2024512386 A5 JP2024512386 A5 JP 2024512386A5
Authority
JP
Japan
Prior art keywords
polypeptides
bispecific antibody
amino acid
heavy chain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/056416 external-priority patent/WO2022189667A1/en
Publication of JP2024512386A publication Critical patent/JP2024512386A/ja
Publication of JP2024512386A5 publication Critical patent/JP2024512386A5/ja
Pending legal-status Critical Current

Links

JP2023555192A 2021-03-12 2022-03-11 非活性化抗体バリアント Pending JP2024512386A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21162341 2021-03-12
EP21162341.8 2021-03-12
PCT/EP2022/056416 WO2022189667A1 (en) 2021-03-12 2022-03-11 Non-activating antibody variants

Publications (2)

Publication Number Publication Date
JP2024512386A JP2024512386A (ja) 2024-03-19
JP2024512386A5 true JP2024512386A5 (cg-RX-API-DMAC7.html) 2025-03-18

Family

ID=74873608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555192A Pending JP2024512386A (ja) 2021-03-12 2022-03-11 非活性化抗体バリアント

Country Status (11)

Country Link
US (1) US20240150484A1 (cg-RX-API-DMAC7.html)
EP (1) EP4305056A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512386A (cg-RX-API-DMAC7.html)
KR (1) KR20230156921A (cg-RX-API-DMAC7.html)
CN (1) CN116964085A (cg-RX-API-DMAC7.html)
AU (1) AU2022231895A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017887A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210971A1 (cg-RX-API-DMAC7.html)
IL (1) IL305636A (cg-RX-API-DMAC7.html)
MX (1) MX2023010567A (cg-RX-API-DMAC7.html)
WO (1) WO2022189667A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4522654A1 (en) 2022-05-12 2025-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
TW202509077A (zh) 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體4結合之抗體
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies
US20260109746A1 (en) 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US20030086929A1 (en) 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP2013507926A (ja) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
ES2929575T3 (es) * 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN107660214B (zh) * 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
SMT202100467T1 (it) * 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
MX2020011552A (es) * 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.

Similar Documents

Publication Publication Date Title
TWI788286B (zh) 三特異性和/或三價結合蛋白
US20260116974A1 (en) Novel anti-cd3epsilon antibodies
US9505848B2 (en) Engineered heterodimeric protein domains
Merchant et al. An efficient route to human bispecific IgG
JP4324231B2 (ja) へテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US11111305B2 (en) Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
AU2015357053B2 (en) Domain-exchanged antibody
JP2020048564A5 (cg-RX-API-DMAC7.html)
US20240059798A1 (en) Conditionally activated antigen binding polypeptide complexes and methods of use thereof
US20230365709A1 (en) Trispecific binders
JP2021094022A5 (cg-RX-API-DMAC7.html)
CN103797033A (zh) 多特异性抗体
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
CN121712805A (zh) Ch3结构域变体或包含该ch3结构域变体的双特异性抗体
JP2024509695A5 (cg-RX-API-DMAC7.html)
CN119343359A (zh) 多特异性抗体的纯化方法
NZ807450A (en) Antibodies binding to gprc5d
NZ778208A (en) Humanized or chimeric cd3 antibodies
NZ772085B2 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123